BridgeBio Pharma Statistics
Total Valuation
BBIO has a market cap or net worth of $6.44 billion. The enterprise value is $7.49 billion.
Important Dates
The next estimated earnings date is Thursday, May 1, 2025, before market open.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BBIO has 190.19 million shares outstanding. The number of shares has increased by 14.30% in one year.
| Current Share Class | 190.19M |
| Shares Outstanding | 190.19M |
| Shares Change (YoY) | +14.30% |
| Shares Change (QoQ) | +0.49% |
| Owned by Insiders (%) | 5.16% |
| Owned by Institutions (%) | 68.42% |
| Float | 139.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.40 |
| Forward PS | 27.42 |
| PB Ratio | -4.42 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 33.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67
| Current Ratio | 4.67 |
| Quick Ratio | 4.44 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.65 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -47.83% |
| Return on Invested Capital (ROIC) | -104.60% |
| Return on Capital Employed (ROCE) | -73.32% |
| Revenue Per Employee | $303,975 |
| Profits Per Employee | -$733,921 |
| Employee Count | 730 |
| Asset Turnover | 0.30 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BBIO has paid $1.15 million in taxes.
| Income Tax | 1.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.66% in the last 52 weeks. The beta is 1.08, so BBIO's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +35.66% |
| 50-Day Moving Average | 33.70 |
| 200-Day Moving Average | 28.81 |
| Relative Strength Index (RSI) | 51.06 |
| Average Volume (20 Days) | 2,795,871 |
Short Selling Information
The latest short interest is 21.71 million, so 11.41% of the outstanding shares have been sold short.
| Short Interest | 21.71M |
| Short Previous Month | 21.76M |
| Short % of Shares Out | 11.41% |
| Short % of Float | 15.61% |
| Short Ratio (days to cover) | 7.74 |
Income Statement
In the last 12 months, BBIO had revenue of $221.90 million and -$535.76 million in losses. Loss per share was -$2.88.
| Revenue | 221.90M |
| Gross Profit | 218.02M |
| Operating Income | -560.87M |
| Pretax Income | -453.82M |
| Net Income | -535.76M |
| EBITDA | -554.79M |
| EBIT | -560.87M |
| Loss Per Share | -$2.88 |
Full Income StatementBalance Sheet
The company has $681.10 million in cash and $1.73 billion in debt, giving a net cash position of -$1.05 billion or -$5.52 per share.
| Cash & Cash Equivalents | 681.10M |
| Total Debt | 1.73B |
| Net Cash | -1.05B |
| Net Cash Per Share | -$5.52 |
| Equity (Book Value) | -1.46B |
| Book Value Per Share | -7.72 |
| Working Capital | 566.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$520.73 million and capital expenditures -$933,000, giving a free cash flow of -$521.66 million.
| Operating Cash Flow | -520.73M |
| Capital Expenditures | -933,000 |
| Free Cash Flow | -521.66M |
| FCF Per Share | -$2.74 |
Full Cash Flow StatementMargins
Gross margin is 98.25%, with operating and profit margins of -252.75% and -241.44%.
| Gross Margin | 98.25% |
| Operating Margin | -252.75% |
| Pretax Margin | -244.34% |
| Profit Margin | -241.44% |
| EBITDA Margin | -250.02% |
| EBIT Margin | -252.75% |
| FCF Margin | n/a |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.30% |
| Shareholder Yield | n/a |
| Earnings Yield | -8.32% |
| FCF Yield | -8.10% |
Dividend DetailsAnalyst Forecast
The average price target for BBIO is $53.00, which is 54.79% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $53.00 |
| Price Target Difference | 54.79% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 59.46% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BBIO has an Altman Z-Score of -4.43 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.43 |
| Piotroski F-Score | 5 |